MINDMAZE THERAPEUTICS HOLDING SA vs Teladoc: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

MINDMAZE THERAPEUTICS HOLDING SA (MMTX.SW)

Q3 20268 Jul – 30 Jul 2026

▼3

Teladoc slashes full-year revenue guidance on Q2 miss Teladoc reported Q2 revenue of $606.9 million, missing estimates, and lowered full-year revenue guidance to $2.362–$2.447 billion. The stock plunged as much as 29% because the cut signals weaker future sales and profits than investors expected.
This is the single biggest new event directly hitting TDOC's price and future outlook.
BetterHelp segment collapses, dragging down overall results BetterHelp revenue fell 12% to $212.6 million and its adjusted EBITDA plunged 96% to just $0.47 million. This sharp deterioration in a key business line raises serious doubts about Teladoc's growth story and profitability.
It explains the specific business weakness behind the guidance cut and why investors are so negative.
Iran conflict drives bond yields up, pressuring growth stocks Trump's vow to strike Iran pushed oil and bond yields higher, causing a risk-off rotation. Teladoc fell 4% as rising yields make future earnings less valuable today, hitting high-multiple growth stocks like TDOC especially hard.
This macro event adds external pressure on TDOC's valuation, compounding its company-specific troubles.

July 20268 Jul – 30 Jul 2026

▼3

Teladoc slashes full-year revenue guidance on Q2 miss Teladoc reported Q2 revenue of $606.9 million, missing estimates, and lowered full-year revenue guidance to $2.362–$2.447 billion. The stock plunged as much as 29% because the cut signals weaker future sales and profits than investors expected.
This is the single biggest new event directly hitting TDOC's price and future outlook.
BetterHelp segment collapses, dragging down overall results BetterHelp revenue fell 12% to $212.6 million and its adjusted EBITDA plunged 96% to just $0.47 million. This sharp deterioration in a key business line raises serious doubts about Teladoc's growth story and profitability.
It explains the specific business weakness behind the guidance cut and why investors are so negative.
Iran conflict drives bond yields up, pressuring growth stocks Trump's vow to strike Iran pushed oil and bond yields higher, causing a risk-off rotation. Teladoc fell 4% as rising yields make future earnings less valuable today, hitting high-multiple growth stocks like TDOC especially hard.
This macro event adds external pressure on TDOC's valuation, compounding its company-specific troubles.

Latest8 Jul – 30 Jul 2026

▼3

Teladoc slashes full-year revenue guidance on Q2 miss Teladoc reported Q2 revenue of $606.9 million, missing estimates, and lowered full-year revenue guidance to $2.362–$2.447 billion. The stock plunged as much as 29% because the cut signals weaker future sales and profits than investors expected.
This is the single biggest new event directly hitting TDOC's price and future outlook.
BetterHelp segment collapses, dragging down overall results BetterHelp revenue fell 12% to $212.6 million and its adjusted EBITDA plunged 96% to just $0.47 million. This sharp deterioration in a key business line raises serious doubts about Teladoc's growth story and profitability.
It explains the specific business weakness behind the guidance cut and why investors are so negative.
Iran conflict drives bond yields up, pressuring growth stocks Trump's vow to strike Iran pushed oil and bond yields higher, causing a risk-off rotation. Teladoc fell 4% as rising yields make future earnings less valuable today, hitting high-multiple growth stocks like TDOC especially hard.
This macro event adds external pressure on TDOC's valuation, compounding its company-specific troubles.